Latha Vairavan is CFO & VP at Arcutis Biotherapeutics, Inc. (ARQT). They have made 6 open-market trades across 1 company since 2025, most recently 2026-05-11.
CIK 0002065881
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ARQT | 85,978 | $2.5M |
Shares reported on the most recent Form 4, priced at the 2026-05-13 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ARQT | SELL | 2026-05-11 | 2026-05-13 | $21.05 | $9K | -4.1% | +10.7% | +19.0% |
| ARQT | SELL | 2026-05-04 | 2026-05-06 | $23.61 | $32K | -12.4% | -7.2% | +13.8% |
| ARQT | SELL | 2026-03-02 | 2026-03-03 | $25.18 | $72K | -3.0% | +0.8% | -8.3% |
| ARQT | SELL | 2026-02-02 | 2026-02-04 | $25.50 | $34K | +1.6% | -8.3% | -10.5% |
| ARQT | SELL | 2025-11-03 | 2025-11-05 | $24.72 | $2K | +9.4% | +30.4% | +9.4% |
| ARQT | SELL | 2025-08-04 | 2025-08-05 | $14.33 | $1K | +12.2% | +7.7% | +64.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.